undamentalytics Newsletter
Sign in

Inhibikase Therapeutics, Inc. (IKT) stock

Add to watchlist

Add holding +

NASDAQ: IKT Nasdaq Biotechnology Next results ~November 13, 2026

Inhibikase Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds68 adding, 37 cuttingOf 20 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 12% in the quarter to 2026-09-30, the 2nd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Inhibikase Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 63% and a beta of 1.5 against the S&P 500.
  • Heavily shorted. 21.9% of the shares available to trade are sold short (29.0 days of average volume to cover).

Latest results

Earnings per share
-$0.11 against an average estimate of -$0.13: beat by 12.0%
Share reaction
-2.4% in the first session after the results on August 11, 2026, against -0.1% for the S&P 500
Next report
November 13, 2026; average EPS estimate -$0.13

Inhibikase Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-0.6%
  • 1 week+1.3%
  • 1 month-23.0%
  • This year-24.9%
  • 1 year+4.8%
  • 5 years-87.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 11, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Results
  4. Share issue
  5. Announcement
  6. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Inhibikase Therapeutics, Inc. valuation models and calculator

No model value for Inhibikase Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 13, 2026, after the close. Analysts expect revenue of $187500 and EPS of −$0.13 (range −$0.16 to −$0.11) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.40 — $187500 0%
Next −$0.42 −5% $250000 +33%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +8.1% on 90 days ago. In the last 30 days, 0 analysts raised Inhibikase Therapeutics, Inc.'s forecast and 1 cut it.

Consensus EPS forecast Inhibikase Therapeutics, Inc., last 90 days
−$0.60 −$0.40 −$0.20 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.37 Current fiscal year, 60 days ago: −$0.44 Current fiscal year, 30 days ago: −$0.45 Current fiscal year, 7 days ago: −$0.45 Current fiscal year, Now: −$0.40 −$0.40 Next fiscal year, 90 days ago: −$0.38 Next fiscal year, 60 days ago: −$0.42 Next fiscal year, 30 days ago: −$0.43 Next fiscal year, 7 days ago: −$0.43 Next fiscal year, Now: −$0.42 −$0.42

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.37−$0.38
60 days ago −$0.44−$0.42
30 days ago −$0.45−$0.43
7 days ago −$0.45−$0.43
Now −$0.40−$0.42

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.13 −$0.11 +12.0%
Jun 2026 −$0.09 −$0.11 −17.9%
Dec 2025 −$0.12 −$0.09 +23.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

10 analysts, Oct 2026
Buy990%
Hold110%
Sell00%

Monthly trend

  1. Oct 202618110
  2. Sep 2026189
  3. Aug 2026189
  4. Jul 2026189

Counts of recommendations published by analysts covering Inhibikase Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
21.9%
of tradable shares
Days to cover
29.01
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
90%
of shares
Held by insiders
6.1%
of shares
Employees
35
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
IKT−79%−66%−58%+156%−37%−25%
Industry peers (median)−35%−56%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
IKT42%25%42%50%42%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
IKT−83%−74%−85%−65%−58%−40%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since December 23, 2020: 99% from December 23, 2020 to October 9, 2023. Getting back needed a 7233% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.41 – $2.52
From 52-week high
−38.9%
vs 50-day average
−25.2%
vs 200-day average
−20.5%
Volatility (1 year)
63%
Beta vs S&P 500
1.48

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
3 up, 6 down
typical move ±5.6%
After a week
2 up, 7 down
typical move ±9.8%
After a month
1 up, 8 down
typical move ±11.2%
Results releasedNext dayS&P 500 next day5 days21 days
August 11, 2026 −2.4% −0.1% −2.4% −5.3%
May 12, 2026 −6.4% +0.4% −22.7% −17.7%
March 26, 2026 +3.1% −3.5% +10.4% +16.0%
November 14, 2025 −5.0% −0.9% −6.9% 0.0%
August 14, 2025 +2.3% −0.2% −1.8% −6.4%
May 14, 2025 −9.0% +0.6% −11.7% −16.6%
March 27, 2025 −4.2% −2.3% −17.4% −7.9%
November 17, 2022 +16.3% +0.1% +8.2% −16.8%
April 1, 2021 −1.3% +2.5% −6.5% −14.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$252M
Institutions reporting
106
Shares held vs prior quarter
▲ 5.6%
Positions opened / closed
19 / 14

Top buyers and sellers, Q2 2026: 68 institutions bought and 37 sold ; the biggest buyer was Nantahala Capital Management, LLC (+2.7M shares) and the biggest seller Perceptive Advisors LLC (−2.3M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sands Capital Alternatives, LLC $26.4M 13.0M 10.5% 0.0%
Soleus Capital Management, L.P. $22.1M 10.9M 8.7% 0.0%
Trails Edge Capital Partners, LP $18.4M 9.1M 7.3% ▲ 12.3%
Fairmount Funds Management LLC $17.5M 8.6M 6.9% 0.0%
Blackrock, Inc. $15.8M 7.8M 6.2% ▲ 23.2%
Kalehua Capital Management LLC $15.5M 7.6M 6.1% ▲ 17.7%
ADAR1 Capital Management, LLC $15M 7.4M 5.9% ▲ 11.8%
Blackstone Inc. $12.1M 5.9M 4.8% 0.0%
Siren, L.L.C. $11.9M 5.8M 4.7% 0.0%
Nantahala Capital Management, LLC $11M 5.4M 4.3% ▲ 100.0%
Commodore Capital LP $11M 5.4M 4.3% 0.0%
Vanguard Capital Management LLC $10M 4.9M 4.0% ▲ 10.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Inhibikase Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $3M 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $3M net buying
Insider Date Trade Shares Price Value
Sands Frank M. 10% owner November 21, 2025 Buy 2,068,965 $1.45 $3M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 11, 2026
  • May 12, 2026
  • March 26, 2026
  • November 14, 2025
  • August 14, 2025
  • May 14, 2025

Recent SEC filings

Data status

When each part of this page on Inhibikase Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Inhibikase Therapeutics, Inc. in brief

What does Inhibikase Therapeutics, Inc. do?
Inhibikase Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Inhibikase Therapeutics, Inc.'s stock ticker?
Inhibikase Therapeutics, Inc. trades under the ticker IKT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Inhibikase Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Sands Capital Alternatives, LLC, Soleus Capital Management, L.P. and Trails Edge Capital Partners, LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Inhibikase Therapeutics, Inc. stock?
Over the last 12 months, Inhibikase Therapeutics, Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Inhibikase Therapeutics, Inc.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Inhibikase Therapeutics, Inc. announces its own schedule.